Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials-Reference-Cited by-同舟云学术

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

Published:2021-09-08 Issue:11 Volume:28 Page:1635-1642
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Gane Edward¹^ORCID,Ledinghen Victor²³^ORCID,Dylla Douglas E.⁴,Rizzardini Giuliano⁵,Shiffman Mitchell L.⁶,Barclay Stephen T.⁷,Calleja Jose Luis⁸^ORCID,Xue Zhenyi⁴,Burroughs Margaret⁴,Gutierrez Julio A.⁹

Affiliation:

1. Faculty of Medicine University of Auckland Auckland New Zealand

2. Centre d’Investigation de la Fibrose Hépatique Bordeaux University Hospital Pessac France

3. INSERM U1053 Bordeaux University Bordeaux France

4. AbbVie Inc North Chicago Illinois USA

5. 1st Division of Infectious Diseases ASST Fatebenefratelli‐Sacco Milan Italy

6. Liver Institute of Virginia Bon Secours Mercy Health Richmond Virginia USA

7. Department of Gastroenterology Glasgow Royal Infirmary Glasgow UK

8. Department of Gastroenterology and Hepatology Hospital Universitario Puerta de Hierro Madrid Spain

9. Scripps Center for Organ and Cell Transplantation La Jolla California USA

Funder

AbbVie

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13600

Reference37 articles.

1. World Health Organization (WHO).Global Hepatitis Report 2017. Accessed 24th February 2021.http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455‐eng.pdf

2. World Health Organization (WHO).Global Health Sector Strategy on Viral Hepatitis. 2016–2021.2016. Accessed 24th February 2021.https://apps.who.int/iris/bitstream/handle/10665/246177/WHO‐HIV‐2016.06‐eng.pdf;jsessionid=B789DC827B02AF7A18F792AB221CF0D5?sequence=1

3. We knowDAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade

4. World Health Organization (WHO).Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.2018. Accessed 24th February 2021.https://www.who.int/hepatitis/publications/hepatitis‐c‐guidelines‐2018/en/

5. AbbVie Inc.Maviret prescribing information. May2020.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals;Journal of Medical Virology;2024-05

2. Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada;Journal of Viral Hepatitis;2024-02-22

3. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

4. Don’t Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C;Clinical Infectious Diseases;2023-11-22

5. Hepatitis C;The Lancet;2023-09